Sanofi India Limited (SANOFI) AI Stock Analysis

18 Followers

Sanofi India Limited

(NSE:SANOFI)

Select Model

Rating:76.7Outperform

Price Target:INR 3,721.00▲(12.44% Upside)

Action:reiterated

Date:11/07/26

Sanofi India’s strong balance sheet, high equity returns, and reliable cash generation are the primary strengths. These are tempered by declining revenue and margins, technical overbought conditions, and trading below the 200-day moving average. Valuation and dividend yield provide moderate support.

Positive Factors

Very Low LeverageThe exceptionally low debt burden gives Sanofi India substantial financial flexibility and resilience. Limited leverage reduces balance-sheet strain, supports continued investment or shareholder distributions, and leaves the company better positioned to withstand operating volatility over the coming quarters.

Negative Factors

Revenue ContractionThe recent revenue decline and uneven trajectory indicate weakening operating momentum rather than dependable expansion. If this pattern persists, slower sales growth could reduce operating leverage, limit reinvestment capacity, and make it harder for the company to compound earnings over the next several quarters.

Sanofi India Limited (SANOFI) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 75.79B
Dividend Yield: 3.72%
Average Volume (3M): 2,270
Price to Earnings (P/E): 20.9
Beta (1Y): 0.81
Revenue Growth: -5.74%
EPS Growth: 2.30%
Country: India
Employees: 1,097
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Sanofi India Limited Business Overview & Revenue Model

Company Description

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company provides pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, thrombosis, infections...

Sanofi India Limited Financial Statement Overview

Summary

Strong balance-sheet stability, negligible leverage, high returns on equity, and robust cash conversion support the score. Persistent revenue declines and gross-margin erosion limit the benefit of otherwise solid profitability.

Income Statement

72Positive

Balance Sheet

92Very Positive

Cash Flow

78Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	17.73B	18.37B	20.13B	19.96B	27.70B	29.57B
Gross Profit	7.86B	7.18B	10.19B	10.31B	15.65B	16.33B
EBITDA	4.33B	4.84B	4.92B	4.93B	7.08B	7.63B
Net Income	3.02B	3.27B	4.13B	6.03B	6.21B	9.44B
Balance Sheet
Total Assets	12.55B	12.55B	16.12B	17.15B	20.72B	30.61B
Cash, Cash Equivalents and Short-Term Investments	2.75B	2.75B	3.40B	3.94B	10.05B	15.38B
Total Debt	178.00M	178.00M	193.00M	190.00M	236.00M	246.00M
Total Liabilities	5.06B	5.06B	7.51B	7.00B	7.96B	8.35B
Stockholders Equity	7.49B	7.49B	8.61B	10.15B	12.76B	22.26B
Cash Flow
Free Cash Flow	2.77B	4.25B	4.25B	1.96B	3.77B	5.36B
Operating Cash Flow	2.91B	4.51B	4.62B	2.30B	3.99B	5.59B
Investing Cash Flow	-71.00M	-253.00M	-192.00M	375.00M	6.51B	6.31B
Financing Cash Flow	-2.73B	-4.46B	-3.92B	-8.78B	-15.83B	-8.49B

Sanofi India Limited Technical Analysis

Technical Analysis SentimentPositive

Last Price3309.20

Price Trends

50DMA3029.88Positive

100DMA3153.78Positive

200DMA3305.13Positive

Market Momentum

MACD100.56Negative

RSI64.63Neutral

STOCH68.84Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SANOFI, the sentiment is Positive. The current price of 3309.20 is above the 20-day moving average (MA) of 3044.45, above the 50-day MA of 3029.88, and above the 200-day MA of 3305.13, indicating a bullish trend. The MACD of 100.56 indicates Negative momentum. The RSI at 64.63 is Neutral, neither overbought nor oversold. The STOCH value of 68.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SANOFI.

Sanofi India Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:SANOFI against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:ABBOTINDIA	81Outperform	INR 566.26B	33.57	―	1.97%	7.21%	9.54%
IN:CIPLA	79Outperform	INR 1.14T	39.58	―	2.05%	-0.74%	-46.77%
IN:SANOFI	77Outperform	INR 76.63B	20.89	―	3.72%	-5.74%	2.30%
IN:GLAND	70Outperform	INR 544.76B	43.53	―	0.61%	21.90%	56.28%
IN:GLAXO	68Neutral	INR 459.23B	40.30	―	2.09%	12.12%	20.03%
IN:PFIZER	67Neutral	INR 179.31B	20.73	―	1.93%	11.75%	2.39%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

IN:SANOFI and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:SANOFI	Sanofi India Limited	3309.20	-1127.81	-25.42%
IN:ABBOTINDIA	Abbott India Limited	26100.20	-2779.85	-9.63%
IN:CIPLA	Cipla Ltd	1417.00	-94.61	-6.26%
IN:GLAND	Gland Pharma Ltd.	3260.70	1447.42	79.82%
IN:GLAXO	GlaxoSmithKline Pharmaceuticals Limited	2726.40	294.62	12.12%
IN:PFIZER	PFIZER LIMITED	3893.40	-1073.18	-21.61%

Sanofi India Limited Corporate Events

Sanofi India Faces GST Show Cause Notice Over Input Tax Credit Claims

Sep 25, 2026

Sanofi India Limited has disclosed that it received a show cause notice from Karnataka GST authorities alleging excess availing of input tax credit for the period April 2022 to March 2023. The Commercial Tax Officer has proposed a tax liability of Rs...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 07, 2026

Sanofi India Limited AI Stock Analysis